Anika Therapeutics Inc. Stock News

Key Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.K.), Galderma (Lausanne, Switzerland), Merz Pharma (Frankfurt, Germany), Revance Therapeutics Inc. (California, U.S.), ALLERGAN (Dublin, Ireland) and other key market players. Key Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.

Complete study of the global Sports Medicines market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the

BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blan

BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences:

BEDFORD, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanch

Zacks Investment Research lowered shares of Anika Therapeutics (NASDAQ:ANIK) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients []

State Street Corp reduced its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 4.6% during the second quarter, Holdings Channel reports. The institutional investor owned 898,395 shares of the biotechnology companys stock after selling 42,958 shares during the period. State Street Corp owned about 0.06% of Anika Therapeutics worth $38,892,000 as of its most []

Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q3 2021 Results - Earnings Call Transcript

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion Desig

BEDFORD, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cher

Anika, now combined with Arthrosurface and Parcus Medical, meets the evolving unmet needs of surgeons in the global joint preservation market Anika, now combined with Arthrosurface and Parcus Medical,

Anika Therapeutics' (ANIK) CEO Cheryl Blanchard on Q2 2021 Results - Earnings Call Transcript

BEDFORD, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans

BEDFORD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans

Anika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2021 Results - Earnings Call Transcript